Cipla Peer Comparison

NSE: CIPLA | BSE: 500087

₹1,423.50

₹3.50 (0.25%)

As on 28-Aug-2026IST

Market cap

₹1,14,554 Cr

Revenue (TTM)

₹28,324 Cr

P/E Ratio

P/B Ratio

3.3

Div. Yield

0.9 %

Edit

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Lupin
Market cap (₹ Cr)	1,14,554	4,60,696	1,91,515	1,18,404	99,455
Revenue (₹ Cr)	28,324	59,911	15,723	28,592	29,967
Net Profit (₹ Cr)	3,364.84	12,172.70	2,156.00	4,492.20	5,551.01
Net Margin (%)	11.54	19.41	13.77	14.92	18.23
RoE (%)	10.63	15.65	26.88	18.78	28.32
Price to Earnings	33.99	38.09	87.81	26.24	17.99
Price-To-Book	3.26	5.33	21.34	4.39	4.18

Income Statement (₹ Cr)

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Lupin
Operating Revenue	28,324.40	59,910.52	15,723.00	28,591.70	29,966.58
Total Income	29,158.75	62,725.79	15,654.00	30,111.40	30,442.31
Total Expenditure	22,985.32	42,647.50	10,532.00	21,334.70	20,428.27
EBITDA	5,339.08	17,263.02	5,191.00	7,257.00	9,538.31
Depreciation	1,304.52	2,976.02	1,511.00	1,724.60	1,529.37
EBIT	4,034.56	14,287.00	3,680.00	5,532.40	8,008.94
Interest	57.37	363.78	634.00	510.20	452.37
Other Income	834.35	2,815.27	-69.00	1,519.70	475.73
Exceptional Items	-275.91	-693.57	-110.00	-534.80	-557.91
Profit before Tax	4,535.63	16,044.92	2,867.00	6,007.10	7,474.39
Provision for Tax	1,170.79	3,872.22	711.00	1,514.90	1,923.38
Profit after Tax	3,364.84	12,172.70	2,156.00	4,492.20	5,551.01

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Lupin
Shareholder's Funds	34,431.95	83,570.09	8,389.00	27,111.40	22,448.27
Minority Interest	14.98	-21.43	25.00	-79.70	-22.18
Non-Current Liabilities	962.15	2,283.44	18,384.00	7,112.50	3,200.22
Current Liabilities	7,013.59	22,622.04	8,343.00	15,711.90	12,651.24
Total Liabilities	42,342.71	1,08,407.20	43,613.69	50,672.60	38,146.06

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Lupin
Non-Current Assets	15,471.21	43,711.29	33,955.00	31,677.20	11,888.82
Current Assets	24,145.86	63,860.29	9,392.00	19,906.10	24,027.38
Total Assets	42,342.71	1,08,407.20	43,613.69	50,672.60	38,146.06
Total Debt*	257.97	4,081.61	14,798.24	11,769.50	5,910.20
Net Current Assets	17,132.27	41,238.25	1,049.00	4,194.20	11,376.14
Contingent Liabilities	987.37	1,587.05	379.25	989.90	1,094.02

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Lupin
Cash From Operating Activities	3,940.02	12,419.18	3,022.71	2,116.60	7,334.50
Cash Flow from Investing Activities	-2,326.13	-11,344.05	-12,712.41	-8,296.10	-3,864.59
Cash from Financing Activities	-1,233.65	-2,512.55	10,150.60	5,806.90	-845.87
Net Cash Inflow / Outflow	380.24	-1,437.42	460.90	-372.60	2,624.04

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Lupin
ROCE (%)	16.00	19.11	19.27	21.39	28.86
ROE (%)	10.63	15.65	26.88	18.78	28.32
ROA (%)	8.42	12.12	7.27	10.03	16.43
EBIT Margin (%)	14.24	23.85	23.41	19.35	26.73
Net Margin (%)	11.54	19.41	13.77	14.92	18.23
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Lupin
Revenue Growth (%)	1.85	11.41	32.85	21.11	28.19
EBIT Growth (%)	-33.61	8.10	20.66	-8.99	77.03
Net Profit Growth (%)	-37.77	16.92	7.69	-3.14	49.13
EPS Growth (%)	-33.63	10.18	12.04	4.31	60.86
Book Value Growth (%)	10.59	15.72	10.51	13.19	30.75

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Lupin
Price / Earnings	32.00	36.48	75.29	24.23	16.68
Price / Book Value	3.26	5.33	21.34	4.39	4.18
Dividend Yield (%)	0.92	0.83	0.75	0.08	0.83
EV/EBITDA	19.82	25.04	39.35	16.95	10.08
Market Cap (₹ Cr)	98,797.18	4,21,639.92	1,42,851.87	87,643.18	1,05,737.27

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Lupin
Debt to Equity	0.00	0.00	1.39	0.12	0.07
Short term debt to equity ratio	0.00	0.05	0.35	0.16	0.18
Current Ratio	3.44	2.82	1.13	1.27	1.90
Quick Ratio	2.50	2.31	0.75	0.91	1.42
Interest Coverage	80.06	45.11	5.52	12.77	17.52

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Lupin
Debtors to sales (%)	19.84	25.89	19.28	18.94	22.04
Asset Turnover	0.71	0.60	0.53	0.64	0.89
Receivable days	52.05	89.14	45.41	33.55	51.23
Inventory Days	57.25	67.85	52.67	33.80	48.93
Payable days	115.96	213.72	244.06	149.82	205.75
Cash Conversion Cycle	-6.65	-56.72	-145.98	-82.46	-105.59

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.